Zymeworks is pleased to announce new and updated clinical and preclinical data presentations at the following medical conferences.
14th Annual World Bispecific Summit
October 2-4, 2023
Boston, MA
Dr. Nina Weisser, Director, Multispecific Antibody Therapeutics at Zymeworks will lead a seminar on Engineering Trispecific T-cell Engagers to Address Biological Challenges in the Treatment of Solid Tumors at 1:30 pm Eastern Time (ET). The presentation will provide an overview of antibody engineering strategies and a review of trispecific t-cell engagers mechanism of action with comparisons to T cell engaging bispecifics and combinations.
AACR-EORTC-NCI
October 11-15, 2023
Boston, Massachusetts
Dr. Raffaele Columbo, Principal Scientist & Group Lead, Medicinal Chemistry at Zymeworks, will present “Refining our understanding of ADCs: Drug development insights from 40 years of data” in Plenary Session 2: The Journey of Antibody Drug Conjugate Development on Thursday, October 12 at 10:00 am ET on Level 3, Ballroom AB of the Hynes Convention Center.
Zymeworks will present clinical data for zanidatamab zovodotin in a poster titled Phase 1 Study of Zanidatamab Zovodotin (ZW49): Safety Profile and Recommended Dose (RD) in Patients with Human Epidermal Growth Factor 2 (HER2)-positive Solid Cancers (Poster #: B130) in Poster Session B on Friday, October 13, 2023 at 12:30 – 4:00 pm ET in Exhibit Hall D, Level 2 of the Hynes Convention Center.
European Society of Medical Oncology (ESMO)
October 20-26, 2023
Madrid, Spain
In partnership with Zymeworks’ zanidatamab collaboration partners, Jazz Pharmaceuticals Ltd. and BeiGene, Ltd., Zymeworks will present updated results from the Phase 1b/2 study of zanidatamab plus chemotherapy and tislelizumab as first-line therapy for patients with advanced HER2-postive gastric/gastroesophageal junction adenocarcinoma in a poster presentation. Additionally, quality of life outcomes from the Phase 2b HERIZON-BTC-01 study evaluating patients with zanidatamab-treated HER2-positive biliary tract cancer will be presented in a poster presentation. More information will be available on Monday, October 16, when abstracts are published on the ESMO website.
14th Annual World ADC San Diego
October 16-19, 2023
San Diego, CA
Dr. Laurence Madera, Senior Scientist at Zymeworks, will present “ZW251 – A novel glypican-3 targeting ADC bearing a topoisomerase I inhibitor payload” in the Translational Session on Tuesday, October 17 at 11:30 am Pacific Time (PT).
Andrea Hernandez, Scientist at Zymeworks, will present “ZW220 – A potential first-in-class TOPO1i ADC for the treatment of NaPi2b-expressing solid tumors” in the Translational Session on Wednesday, October 18 at 12:30 pm PT.
Society for Immunotherapy of Cancer (SITC)
November 1-5, 2023
San Diego, CA
Zymeworks will present two abstracts on our tri-specific t-cell engager (TriTCE) programs in poster presentations at the SITC Conference:
Title: TriTCE Co-Stim: A novel trispecific T cell engager platform, with integrated CD28 costimulation, engineered to widen the therapeutic window for treatment of poorly infiltrated tumors.
Abstract Number: 1372
Date and Time: Saturday, November 4, 2023 at 9:00 am – 8:30 pm PT
Location: Exhibit Halls A and B1, San Diego Convention Center
Title: TriTCE CPI: a novel trispecifc T cell engager platform with integrated PD-1/PD-L1 checkpoint inhibition engineered for the treatment of immunosuppressed tumors
Abstract Number: 1396
Date and Time: Saturday, November 4, 2023 at 9:00 am – 8:30 pm PT
Location: Exhibit Halls A and B1, San Diego Convention Center
All presentations will be available to conference registrants on the conference website as well as to the general public at www.zymeworks.com/publications at the time of presentation at the conference.
